Rolandic Epilepsy (Centrotemporal Epilepsy) Summary

29 relevant articles (0 outcomes, 4 trials/studies) found for this Disease

Description: An autosomal dominant inherited partial epilepsy syndrome with onset between age 3 and 13 years. Seizures are characterized by PARESTHESIA and tonic or clonic activity of the lower face associated with drooling and dysarthria. The episodes tend to occur at night and may become secondarily generalized. In most cases, affected children are neurologically and developmentally normal. The electroencephalogram shows characteristic high-voltage sharp waves over the central temporal regions, which are more prominent during drowsiness and sleep. In general, seizures do not continue beyond mid-adolescence. (From Epilepsia 1998 39;Suppl 4:S32-S41)

Also Known As: Centrotemporal Epilepsy; Epilepsy, Rolandic; BCECTS; Benign Epilepsy, Childhood, Centrotemporal Spikes; Benign Rolandic Epilepsy Show All >>

Key Drugs and Agents for Rolandic Epilepsy

Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:

Silver Sulfadiazine (SSD) : 1 study in 1 result : FDA 4 Generic
Penicillins (Penicillin) : 1 study in 1 result : FDA 1
Glucose (Dextrose) : 1 study in 1 result : FDA 183 Generic
zaleplon (Sonata) : 1 study in 1 result : FDA 4
Carbamazepine (Tegretol) : 8 results : FDA 23 Generic
Anticonvulsants (Antiepileptic Drugs) : 3 results : IBA
Valproic Acid (Valproate, Semisodium) : 2 results : FDA 37 Generic
Immunoglobulin E (IgE) : 2 results : IBA
topiramate (Topamax) : 2 results : FDA 16
lamotrigine (Lamictal) : 2 results : FDA 17 Generic

Show All >>

Diseases Related to Rolandic Epilepsy

Show All >>

Key Therapies for Rolandic Epilepsy

Efficacy Chart >>

High-Frequency Ventilation : 1 result